15300 Maintenance of response through up to 4-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial

Abstract

Introduction: Guselkumab (GUS) is a fully-human monoclonal antibody that binds and inhibits the p19 subunit of IL-23. In the VOYAGE 2 phase 3, randomized, double-blind, placebo/active comparator-controlled clinical trial of moderate to severe psoriasis (PsO), significantly greater proportions of GUS-treated patients achieved PASI90 response and Investigator Global Assessment (IGA) 0/1 scores vs placebo (PBO) at wk 16 vs adalimumab (ADA) at wk 24. Here, results following up to 4 years of continuous GUS treatment are presented.